Wyeth Pharmaceuticals: Premarin®, Prempro® and Hormone Replacement Therapy (A)
Kathryn I. C. Huang and Megan E. Vanaelstyn
University of Notre Dame, USA
Volume 1 Issue 1: 2004, pp. 7-26; ABSTRACT
Millions of women worldwide between the ages of 45 and 55 experience the effects of menopause and have sought both treatment and relief in the form of hormone replacement therapy. Wyeth Pharmaceuticals, a division of Wyeth, Inc., is the market leader in prescription drug treatment for menopause with Premarin®, a blend of natural estrogens (for women who have had a hysterectomy); Prempro®, a one-tablet hormone replacement therapy consisting of natural estrogens plus progestin. A stunning set of results from the Women’s Health Initiative, released in the summer of 2002, however, challenges conventional approaches to treatment and poses a significant threat to Wyeth share price and market leadership.
ORDER ARTICLE PERMISSIONS/REPRINTS/OFFPRINTS
To order permissions to include this article in textbooks, edited volumes, course booklets, online/digital course packs, etc., and/or to order multiple individual hard copies for classroom use, please use the appropriate form available on the Order Forms page or alternatively, contact the Publishing Editor pneilson@neilsonjournals.com directly.
